Fragnaud Henri, Mattei Jean-Camille, Le Nail Louis-Romée, Nguyễn Mỹ-Vân, Schubert Thomas, Griffin Anthony, Wunder Jay, Biau David, Gouin François, Bonnevialle Paul, Vaz Gualter, Ropars Mickael, Crenn Vincent
Orthopedics and Trauma Department, University Hospital Hotel-Dieu, CHU Nantes, Nantes, France.
Ramsay Santé, Hôpital Privé Clairval, Marseille, France.
Front Surg. 2022 Jul 12;9:965951. doi: 10.3389/fsurg.2022.965951. eCollection 2022.
Bone metastases in thyroid cancer impair the patient's quality of life and prognosis. Interestingly, wide margins resection as the surgical treatment of bone metastases might improve the overall survival (OS). Nonetheless, data are lacking regarding the potential benefits of this strategy.
In order to assess the OS of patients with thyroid cancer after a bone metastases carcinologic resection, a retrospective multicentric study was performed, evaluating the 1, 5, 10 and 15 years-OS along with the potential prognosis associated factors.
40 patients have been included in this multicentric study, with a mean follow-up after surgery of 46.6 ± 58 months. We observed 25 (62.5%) unimestastatic patients and 15 multimetastatic patients (37.5%). The median overall survival after resection was 48 ± 57.3 months. OS at 1, 5, 10, and 15 years was respectively 76.2%, 63.6%, 63.6%, and 31.8%. Survival for patients with a single bone metastasis at 15 year was 82.3%, compared with 0.0% (Log Rank, = 0.022) for multi-metastatic bone patients.
This study advocates for an increased long term 10-year OS in patients with thyroid cancer, after resection of a single bone metastasis, suggesting the benefits of this strategy in this population.
甲状腺癌骨转移会损害患者的生活质量和预后。有趣的是,作为骨转移手术治疗方法的广泛切缘切除可能会改善总生存期(OS)。尽管如此,关于该策略潜在益处的数据仍然缺乏。
为了评估骨转移癌切除术后甲状腺癌患者的总生存期,进行了一项回顾性多中心研究,评估1年、5年、10年和15年的总生存期以及潜在的预后相关因素。
40例患者纳入了这项多中心研究,术后平均随访时间为46.6±58个月。我们观察到25例(62.5%)单发性转移患者和15例多发性转移患者(37.5%)。切除术后的中位总生存期为48±57.3个月。1年、5年、10年和15年的总生存率分别为76.2%、63.6%、63.6%和31.8%。单发性骨转移患者15年的生存率为82.3%,而多发性骨转移患者为0.0%(对数秩检验,P = 0.022)。
本研究支持甲状腺癌患者在切除单发性骨转移后可提高长期(10年)总生存率,表明该策略对这一人群有益。